CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 116 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,635,073 | +93.1% | 59,414 | +138.1% | 0.00% | – |
| Q2 2023 | $846,791 | -65.3% | 24,957 | -63.2% | 0.00% | -100.0% |
| Q1 2023 | $2,441,567 | +26.8% | 67,859 | +57.0% | 0.00% | 0.0% |
| Q4 2022 | $1,925,825 | +105.5% | 43,209 | +29.7% | 0.00% | – |
| Q3 2022 | $937,000 | -80.2% | 33,310 | -81.0% | 0.00% | -100.0% |
| Q2 2022 | $4,731,000 | -26.7% | 175,506 | -7.4% | 0.00% | 0.0% |
| Q1 2022 | $6,455,000 | +54.3% | 189,509 | +75.0% | 0.00% | +100.0% |
| Q4 2021 | $4,184,000 | -4.1% | 108,300 | +34.0% | 0.00% | 0.0% |
| Q3 2021 | $4,365,000 | +20.0% | 80,848 | -25.7% | 0.00% | 0.0% |
| Q2 2021 | $3,639,000 | +111.2% | 108,836 | +30.1% | 0.00% | – |
| Q1 2021 | $1,723,000 | +1.7% | 83,664 | -13.5% | 0.00% | – |
| Q4 2020 | $1,695,000 | +159.2% | 96,732 | +119.3% | 0.00% | – |
| Q3 2020 | $654,000 | -44.9% | 44,100 | -51.7% | 0.00% | – |
| Q2 2020 | $1,187,000 | – | 91,276 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |